XML 24 R5.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) - USD ($)
$ in Thousands
Series B Non-Voting
Series A
Series B Non-Voting
Series A Non-Voting
Series B Non-Voting
Convertible Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Balances at Feb. 05, 2024 $ 3 $ (2) $ 1
Balances (in Shares) at Feb. 05, 2024       3,197,975      
Issuance of common stock $ 2 (2)
Issuance of common stock (in Shares)       2,207,553      
Issuance of Series A convertible preferred stock, net of issuance costs of $69 $ 2,931
Issuance of Series A convertible preferred stock, net of issuance costs of $69 (in Shares) 20,000,000            
Stock-based compensation expense 17 17
Net loss (7,077) (7,077)
Balances at Mar. 31, 2024 $ 2,931 $ 5 13 (7,077) (7,059)
Balances (in Shares) at Mar. 31, 2024 20,000,000     5,405,528      
Balances at Feb. 05, 2024 $ 3 (2) 1
Balances (in Shares) at Feb. 05, 2024       3,197,975      
Net loss             (57,943)
Balances at Sep. 30, 2024 $ 52,841 $ 2,931 $ 35 397,345 (57,943) 342,368
Balances (in Shares) at Sep. 30, 2024   2,439 137,138 34,998,550      
Balances at Mar. 31, 2024 $ 2,931 $ 5 13 (7,077) (7,059)
Balances (in Shares) at Mar. 31, 2024 20,000,000     5,405,528      
Stock-based compensation expense 321 321
Net loss (22,243) (22,243)
Balances at Jun. 30, 2024 $ 2,931 $ 5 334 (29,320) (28,981)
Balances (in Shares) at Jun. 30, 2024 20,000,000     5,405,528      
Stock-based compensation expense         1,750   1,750
Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse recapitalization $ (2,931) $ 2,931 2,931
Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse recapitalization (in Shares) (20,000,000)   137,138        
Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization $ 3 26,445 26,448
Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization (in Shares)       2,722,207      
Issuance of common stock and pre-funded warrants in the Pre-Closing Financing, $ 20 248,437 248,457
Issuance of common stock and pre-funded warrants in the Pre-Closing Financing, (in Shares)       20,061,932      
Issuance costs of Pre-Closing Financing and reverse recapitalization (20,480) (20,480)
Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the reverse recapitalization $ 1 4,999 5,000
Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the reverse recapitalization (in Shares)       1,208,883      
Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing $ 56,097 $ 6 144,433 144,439
Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing (in Shares)   2,439   5,600,000      
Issuance cost of PIPE Financing   $ (3,256)     (8,573)   (8,573)
Net loss (28,623) (28,623)
Balances at Sep. 30, 2024 $ 52,841 $ 2,931 $ 35 $ 397,345 $ (57,943) $ 342,368
Balances (in Shares) at Sep. 30, 2024   2,439 137,138 34,998,550